Outpatient Control-to-Range: System and Monitoring Testing

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

DiAs Diabetes Assistant Wearable Artificial Pancreas Platform

Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.

Trial Locations (1)

93105

Sansum Diabetes Research Institute, Santa Barbara

All Listed Sponsors
collaborator

University of California, Santa Barbara

OTHER

collaborator

University of Virginia

OTHER

lead

Sansum Diabetes Research Institute

OTHER

NCT01697150 - Outpatient Control-to-Range: System and Monitoring Testing | Biotech Hunter | Biotech Hunter